New drug shows promise against Tough-to-Treat bile duct cancers

NCT ID NCT04466891

Completed Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested an experimental drug called ZW25 for people with advanced bile duct cancers that have a specific genetic feature called HER2 amplification. The trial involved 87 patients whose cancer had progressed after standard chemotherapy. Researchers measured how well the drug shrank tumors, how long responses lasted, and monitored side effects to see if ZW25 could help control this difficult-to-treat cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Advent Health Cancer Institute

Orlando, Florida, 32804, United States
Affiliated Tumor Hospital of Harbin Medical University

Harbin, 150081, China
Affiliated Zhongshan Hospital of Fudan University

Shanghai, 200032, China
Anhui Provincial Hospital

Hefei, 230001, China
Asan Medical Center Hospital

Seoul, 05505, South Korea
Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Beijing Cancer Hospital

Beijing, 100142, China
Centro de Cáncer Nuestra Señora de la Esperanza

Santiago, 8330032, Chile
City of Hope National Medical Center

Duarte, California, 91010, United States
Corporacio Sanitaria Parc Tauli

Sabadell, 08208, Spain
Département De Médecine

Villejuif, 94805, France
Département Oncologie Gastro-entérologie CHRU de Poitiers La Miletrie

Poitiers, 86000, France
Fondazione del Piemonte per l'Oncologia (IRCCS)

Candiolo, 10060, Italy
Gyeongsang National University Hospital

Jinju, 52727, South Korea
Hopitaux de La Timone

Marseille, 13385, France
Hospital General Universitario Gregorio Marañón

Madrid, 28007, Spain
Hospital Miguel Servet

Zaragoza, 50009, Spain
Hospital Universitario Doce de Octubre

Madrid, 28041, Spain
Hospital Universitario Reina Sofia

Córdoba, 14004, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Hubei Cancer Hospital

Wuhan, 430079, China
Hunan Cancer Hospital

Changsha, 410013, China
Huzhou Central Hospital

Huzhou, 313000, China
Imperial College Healthcare NHS Trust

London, W12 0HS, United Kingdom
Institut de Cancerologie et d'Hematologie Hopital Morvan - CHRU de Brest

Brest, 29200, France
Istituto Clinico Humanitas

Milan, 20089, Italy
Istituto Nazionale Dei Tumori

Milan, 20133, Italy
Istituto Oncologico Veneto - I.R.C.C.S.

Padua, 35128, Italy
Jilin Cancer Hospital

Changchun, 130012, China
Jinhua Central Hospital

Jinhua, 321000, China
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

Nanjing, 210008, China
Oncologie médicale Hopital Jean Minjoz

Besançon, 25030, France
Oregon Health and Science University

Portland, Oregon, 97239, United States
Peking Union Medical College Hospital

Beijing, 100730, China
Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
Pusan National University Hospital

Pusan, 49241, South Korea
Radiomed (Clinica Alemana de Temuco)

Temuco, 645, Chile
Royal Free London NHS Foundation Trust

London, NW3 2QG, United Kingdom
Samsung Medical Center

Seoul, 06351, South Korea
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Seoul National University Bundang Hospital

Seongnam, 13620, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System

Seoul, 03722, South Korea
Shandong Provincial Third Hospital

Shandong, 250031, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, 310016, China
The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, 06591, South Korea
The First Affiliated Hospital of Zhejiang University

Hangzhou, 310003, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, 450052, China
The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, 510080, China
The First Hospital Of Lanzhou University

Lanzhou, 730000, China
The Oncology Institute of Hope and Innovation

Whittier, California, 90603, United States
The Third Affiliated Hospital of the Chinese PLA

Shanghai, 200081, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, 300060, China
Universitario Germans Trias i Pujol

Barcelona, 08916, Spain
University College London Hospitals (UCLH)

London, NW1 2PG, United Kingdom
University of Arizona Cancer Center

Tucson, Arizona, 95724, United States
University of California Los Angeles

Santa Monica, California, 90404, United States
University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Texas Southwestern Medical Center - Hospital

Dallas, Texas, 75390, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Weifang People's Hospital

Weifang, 261000, China
West China Hospital

Chengdu, 610041, China
Winship Cancer Institute, Emory University

Atlanta, Georgia, 30322, United States
Zhejiang Cancer Hospital

Hangzhou, 310022, China
Zhejiang Provincial People's Hospital

Hangzhou, 310014, China

Conditions

Explore the condition pages connected to this study.

HER2-AMPLIFIED BILIARY TRACT CANCERS